MK-7075 (Miransertib) in Proteus Syndrome
Condition(s):Proteus SyndromeLast Updated:March 12, 2024Recruiting
Hide Studies Not Open or Pending
Condition(s):Proteus SyndromeLast Updated:March 12, 2024Recruiting
Condition(s):Proteus SyndromeLast Updated:June 30, 2022Completed
Condition(s):PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS)Last Updated:July 3, 2023Active, not recruiting
Condition(s):PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus SyndromeLast Updated:April 13, 2023Terminated
Condition(s):Proteus Syndrome; PIK3CA Related Overgrowth SpectrumLast Updated:March 27, 2024Recruiting
Condition(s):Proteus Syndrome; PIK3CA-Related Overgrowth Spectrum (PROS); Growth DisordersLast Updated:August 6, 2021No longer available
Condition(s):Coronary Artery Disease; Proteus Syndrome; Coffin – Sins Syndrome; Familial Isolated Hyperparathyroidism; Dubouitz SyndromeLast Updated:July 26, 2018Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.